File: '\\swfile\EmailIn\20260615 104220 Attachment Asep NR_Paul Kania to BoD_061126.docx'

Asep Medical Holdings Inc.

2

Asep Medical Holdings Inc.

Appoints Mr. Paul Kania to its Board of Directors

VANCOUVER, BC, June 15, 2026 - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce the appointment of Mr. Paul Kania to its board of directors, effective immediately.

Mr. Kania brings more than 20 years of experience in accounting, finance, and corporate governance to Asep. He is the Founder of PLK Accounting & Finance Inc., a firm that provides C-suite leadership and board advisory services to both private and publicly traded companies.

Prior to founding PLK, Mr. Kania built an impressive career with leading financial and professional services organizations. He worked as an auditor with MNP LLP in Toronto and Berdon LLP in New York City before joining Brookfield Asset Management, where he served as a manager within the company's Corporate Finance department.

"Paul's extensive financial expertise, public company experience, and strong understanding of corporate governance will be invaluable as the Company continues to advance its strategic objectives," said Richard Heinzl, Interim CEO of Asep. "We are delighted to welcome him to our Board and look forward to benefiting from his insight and leadership."

Mr. Kania holds a Bachelor of Arts (Honours) degree in Economics and Philosophy from the University of Toronto and a Finance and Accounting Certificate from Toronto Metropolitan University. He is also an unregistered Certified Public Accountant with the State of New York.

"I am excited to join Asep's Board of Directors at such an important stage in the Company's growth," said Mr. Kania. "The Company has the potential to address critical healthcare challenges, and I look forward to supporting its mandate as it works to create value for patients, partners, and shareholders."

The appointment reflects Asep's continued commitment to strengthening its leadership team and governance capabilities as the Company advances its mission to improve outcomes for patients affected by sepsis and other life-threatening infections.

ABOUT ASEPMEDICAL HOLDINGS INC.

Asep Medical Holdings is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

FOR MORE INFORMATION, PLEASE CONTACT -

Chris Dallin, Marketing Director

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. +1 (604) 362-3654

FORWARD-LOOKING STATEMENTS -

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the ability of the joint venture to pursue commercialization of the Sepsis diagnostic testing kit in China; the contributions of the joint venture partner to the joint venture; the ability of the joint venture to secure the necessary regulatory approvals for the diagnostic testing kit; the successful clinical testing of Sepset's Sepsis in vitro diagnostic test and its intended filing for regulatory market authorization; the Company not receiving regulatory market authorization as planned or at all; the undertaking of pre-clinical studies on our lead therapeutic, with the expectation that this will lead to fast-track clinical trials; the timeframe for identification of sepsis with the Company's products; the potential opportunities for the generation of revenue; the therapeutic benefits of the Company's products; and other statements regarding the Company's proposed business plans. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks including the risk that the Company's products may not perform as expected; that the Company may not receive the requisite regulatory market authorization or results of testing; the Company's testing of the products may not be successful and market authorization may not be obtained in the estimated timelines or at all; the Company may not be able to generate revenue from its products as expected or at all; the joint venture may not be able to commercialize the diagnostic testing kit in China as expected or at all; the market for the Company's products may not be as described in this news release; and various other risk factors identified in the Asep's public disclosure record, including without limitation the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.